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LETTERS TO THE EDITOR
CONCURRENCE OF
FACIOSCAPULOHUMERAL MUSCULAR
DYSTROPHY AND MYASTHENIA GRAVIS
We describe the diagnostic and management problems
related to the association of facioscapulohumeral muscu-
lar dystrophy (FSHD) and myasthenia gravis (MG) in two
unrelated patients in whom the diagnosis and hence treat-
ment of myasthenia was delayed because progressive mus-
cle weakness was ascribed erroneously to the underlying
muscular dystrophy.
The ﬁrst patient was a 69-year-old man who had been
clinically diagnosed with FSHD, conﬁrmed by deletion
analysis (33 kb) 2 years prior to admission, who came to
our attention because of the sudden onset of dyspnea,
dysphagia, dysarthria, ptosis, and severe weakness of all
limbs. Electromyography (EMG) revealed ﬁndings sugges-
tive of myopathy. Repetitive nerve stimulation produced a
decremental response suggestive of myasthenia gravis.
Acetylcholine receptor-binding antibodies were present
(12 pmol/L). Muscle biopsy of the biceps brachii demon-
strated an increased variability of ﬁber size, ﬁber splitting,
type II ﬁber predominance, and several necrotic ﬁbers
with cellular inﬁltrates (Fig. 1). Dystrophin, utrophin, and
sarcoglycan antibody staining were normal. The patient
was started on dexamethasone (25 mg daily), azathioprine
(50 mg daily), and pyridostigmine (270 mg daily) with
remarkable improvement.
The second patient was a 60-year-old man who presented
for evaluation of ﬂuctuating dysarthria that began 8 months
earlier. On a few occasions he had choked while swallowing.
For 5–10 years, he had noticed mild ﬂuctuating difﬁculty in
raising his arms over his head, carrying heavy items, and
standing up straight. There was no family history of weakness.
On examination there was mild dysarthria and facial and
limb-girdle muscle weakness (MRC grade 4). Acetylcholine
receptor-binding antibodies were present (4.1 pmol/L). Se-
rum creatine kinase showed a 1.5-fold elevation. The FSHD
diagnosis was conﬁrmed by deletion analysis (33 kb). EMG
showed short-duration motor unit potentials. Repetitive
nerve stimulation produced a decremental response. Pyri-
dostigmine produced modest beneﬁt. Following treatment
with mycophenolate mofetil (1000 mg twice daily), the dys-
arthria and dysphagia improved.
Previous authors have observed the concurrence of
myasthenia gravis with myotonic dystrophy5 or limb-girdle
muscular dystrophy,2 and in another family with familial
FSHD.6
In our Case 1, the diagnosis of MG may have been
delayed because at least part of the initial symptoms of
fatigability and shortness of breath attributed to FSHD
were probably due to untreated MG. Although rare
(1%), respiratory dysfunction alone may be the present-
ing symptom of MG.4 Although atypical phenotypes, such
as progressive external ophthalmoplegia, have been de-
scribed in one family with FSHD,3 the diagnosis of FSHD
was questioned when ptosis and severe bulbar dysfunction
developed. In Case 2, the diagnosis of MG and FSHD were
made at the same time. It is possible, however, that the
ﬂuctuation of proximal weakness noticed prior to the
onset of additional bulbar symptoms might have been due
to untreated MG.
Up to 80% of muscle biopsies from patients with FSHD
show some degree of mononuclear inﬂammatory cell in-
ﬁltration.1 It has been suggested that FSHD is an inﬂam-
matory myopathy, but biopsies do not contain non-ne-
crotic muscle ﬁbers focally invaded by T-cells,1 patients do
not beneﬁt from prednisone treatment when assessed
carefully by computerized muscle testing in controlled
trials,7 and the presence of abundant mononuclear inﬁl-
trates does not affect disease progression.7 Although the
usual diagnostic approach is to unify symptoms and ﬁnd-
ings under a single diagnosis, the association of myasthe-
nia gravis with FSHD in our two patients is intriguing and
raises the possibility that immune mechanisms may be
operative in FSHD.8
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AIR STACKING FOR COUGH ASSISTANCE
I read with interest the review by Perrin et al.6 and
found it comprehensive except for one important
omission. The authors failed to note “air stacking” or
the importance of maximal lung insufﬂations prior
to attempts at manually assisted coughing.4 Likewise,
they recommended using mechanical insufﬂation–
exsufﬂation (CoughAssist; J. H. Emerson Co., Cam-
bridge, MA) at insufﬂation pressures of 20 cm H2O,
essentially the pressure required for normal tidal
volumes in normally compliant lungs. However, the
principal reason that we are able to manage patients
with neuromuscular diseases without needing to re-
sort to tracheotomy (with the sole exception of pa-
tients with advanced bulbar ALS)2,3 is the effective
airway secretion elimination afforded by optimal as-
sisted coughing, that is, manual cough assist from
the deep lung volumes of maximally insufﬂated
lungs.4 Undoubtedly, the reticence to expand lungs
to the 60–70 cm H2O pressures that we use routinely
stems from the fear of barotrauma so common in
patients with primarily lung disease and yet clinically
nonexistent in our 800 noninvasive ventilation users.
Indeed, our patients invariably ﬁnd insufﬂation pres-
sures of less than 35 cm H2O to be ineffective or
minimally effective at best. Although an average tidal
volume may be 600 ml, an average effective cough
volume is 2300 ml.5 It is no surprise that studies that
employ nocturnal-only nasal ventilation and ignore
effective assisted coughing methods result in mini-
mal beneﬁts to patient longevity.1 Any review article
on long-term noninvasive ventilation is incomplete
without recommendations for optimally effective as-
sisted coughing.
J. Bach, MD
Department of Physical Medicine and Rehabilitation, University
Hospital B-403, University of Medicine and Dentistry of New
Jersey, 150 Bergen Street, Newark, New Jersey 07103-2406
1. Bach JR. Conventional approaches to managing neuromuscu-
lar ventilatory failure. In: Bach JR, editor. Pulmonary rehabil-
itation: the obstructive and paralytic conditions. Philadelphia:
Hanley & Belfus; 1996. p 285-301.
2. Bach JR, Baird JS, Plosky D, Nevado J, Weaver B. Spinal mus-
cular atrophy type 1: management and outcomes. Pediatr Pul-
monol 2002;34:16–22.
3. Gomez-Merino E, Bach JR. Duchenne muscular dystrophy:
prolongation of life by noninvasive respiratory muscle aids.
Am J Phys Med Rehabil 2002;81:411–-415.
FIGURE 1. Biceps muscle biopsy from case 1, hematoxylin and eosin, 20. (a) Note the variability in ﬁber size, ﬁber splittings, and mild
increase of perifascicular tissue. (b) Note the enlarged blood vessel inﬁltrated with inﬂammatory cells.
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Reply
We thank Dr. Bach for highlighting the importance of
assisting cough in patients with respiratory insufﬁciency
due to neuromuscular disease. This is a point we tried to
emphasize in our review. Dr. Bach points out that we failed
to mention “air stacking”; this was edited out of an earlier
draft for the sake of brevity. However, we acknowledge that
“air” or “breath” stacking can be a useful strategy to en-
hance cough effectiveness. The technique requires the use
of a volume-limited (not bilevel) ventilator and intact glot-
tic function. The patient retains several consecutive venti-
lator breaths by closing the glottis after each breath and
achieves a total tidal volume that may exceed 2 L, depend-
ing on body size. The greater elastic force at these higher
lung volumes enables the patient to attain greater airﬂow
during cough, as found in earlier studies by Dr. Bach.1
With regard to his point about greater insufﬂation
pressures during mechanical insufﬂation–exsufﬂation, we
cannot entirely agree with Dr. Bach. We concur that an
inspiratory pressure of 20 cm H2O is on the low side,
usually used only initially when patients are adapting to
the technique. We most often use insufﬂation pressures
closer to the upper end of the 20–40 cm H2O range that
we suggested in our review (i.e., 35–40 cm H2O) for
greater enhancement of cough. However, the 60–70 cm
H2O pressures suggested by Dr. Bach seem a bit high. In
two recent articles on mechanical insufﬂation, the ranges
given are closer to the range we gave in our article. In one
by Sancho et al.3 pressures used were 40 and 40 cm
H2O for insufﬂation and exsufﬂation, respectively, and in
a second by Miske et al.2 on children with neuromuscular
disease, insufﬂation pressures ranged from 15 to 40 cm
H2O and exsufﬂation pressures from30 to50 cm H2O.
We would be reluctant to endorse the routine use of
pressures as high as those suggested by Dr. Bach without
better documentation of safety.
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